Results 141 to 150 of about 25,762 (279)

Safety and efficacy of eculizumab in adult and pediatric patients with aHUS, with or without baseline dialysis [PDF]

, 2015
C
Hourmant, Maryvonne, Kincaid, John F, Legendre, Christophe M, Menne, Jan, van de Kar, Nicole CAJ, Vande Walle, Johan   +5 more
core   +1 more source

Actualización en síndrome hemolítico urémico atípico: diagnóstico y tratamiento. Documento de consenso [PDF]

, 2016
Trobareu una actualització (2015) d'aquest document a: http://hdl.handle.net/2445/99427Haemolytic uraemic syndrome (HUS) is a clinical entity defined as the triad of nonimmune haemolytic anaemia, thrombocytopenia, and acute renal failure, in which the ...
Arias, Manuel, Ariceta, Gema, Blasco, Miguel, Campistol Plana, Josep M., Espinosa, Mario, Grinyó Boira, Josep M., Praga, Manuel, Rodríguez de Córdoba, Santiago, Torra, Roser, Vilalta, Ramon (Vilalta Casas)   +9 more
core   +1 more source

Atypical Hemolytic‐Uremic Syndrome: An Update on Pathophysiology, Diagnosis, and Treatment

Therapeutic apheresis and dialysis, 2018
Atypical hemolytic uremic syndrome (aHUS), a rare variant of thrombotic microangiopathy, is characterized by microangiopathic hemolytic anemia, thrombocytopenia, and renal impairment.
R. Raina, Vinod Krishnappa, T. Blaha, T. Kann, W. Hein, Linda Burke, A. Bagga   +6 more
semanticscholar   +1 more source

Complement factor h-antibody-associated hemolytic uremic syndrome: pathogenesis, clinical presentation, and treatment. [PDF]

, 2014
The presence of circulating autoantibodies, primarily to complement factor H antibodies (CFH-Abs) in plasma characterizes the autoimmune form of atypical hemolytic uremic syndrome (aHUS).
Giner, T., Hofer, J., Józsi, Mihály
core   +1 more source

Should eculizumab be discontinued in patients with atypical hemolytic uremic syndrome? [PDF]

, 2017
Eva Rodríguez, Clara Barrios, María José Soler   +2 more
openalex   +1 more source

Eculizumab in the Treatment of Acetylcysteine-Induced Atypical Hemolytic Uremic Syndrome [PDF]

, 2023
Arielle Jalbert, Han Yao, Mylène Fagnan, Benoît Crevier   +3 more
openalex   +1 more source

Postoperative atypical hemolytic uremic syndrome in nontransplant setting: A case report with review of literature

Global Journal of Transfusion Medicine, 2018
Atypical hemolytic uremic syndrome (aHUS) is a clinical diagnosis characterized by a triad of microangiopathic hemolytic anemia, thrombocytopenia, and renal dysfunction. Postoperative aHUS in nontransplant patients is a rare entity.
Anil Khetarpal, Vidhi Gupta, Urvershi Kotwal   +2 more
doaj   +1 more source

Atypical hemolytic-uremic syndrome, manifesting without thrombocytopenia (clinical case)

Известия высших учебных заведений. Поволжский регион: Медицинские науки
Background. Atypical hemolytic uremic syndrome is an ultra-rare (orphan) disease from the group of thrombotic microangiopathies of progressive course, which is caused by uncontrolled activation of the alternative complement pathway of hereditary or ...
A.A. Dyachkova, A.N. Anokhin, M.A. Shlykova, I.S. Kiseleva   +3 more
doaj   +1 more source

First-line therapy in atypical hemolytic uremic syndrome: consideration on infants with a poor prognosis. [PDF]

, 2014
BackgroundAtypical hemolytic uremic syndrome (aHUS) is a rare and heterogeneous disorder. The first line treatment of aHUS is plasma therapy, but in the past few years, the recommendations have changed greatly with the advent of eculizumab, a humanized ...
A Szilagyi, Aspazija Sofijanova, Attila Szabó, C Loirat, CM Legendre, D Kavanagh, D Magen, F Fakhouri, F Fakhouri, G Ariceta, G Ariceta, György Reusz, J Caprioli, J Zuber, J Zuber, JM Campistol, Klaus Arbeiter, Krisztina Rusai, Lilla Szeifert, LM Geerdink, M Christmann, M Heurich, M Jozsi, M Lemaire, M Reti, MA Abrera-Abeleda, MA Dragon-Durey, Miklós Szabó, N Besbas, Nóra Szarvas, RA Gruppo, RL Ruebner, S Jung, Thomas Müller, Valbona Nushi-Stavileci, Velibor Tasic, Z Prohaszka, Zoltán Prohászka, Zoran Gucev, Ágnes Szilágyi   +39 more
core   +1 more source

Managing atypical hemolytic uremic syndrome: chapter 2 [PDF]

Kidney International, 2015
Licht et al. present the 2-year follow-up data of the landmark trials studying the efficacy of eculizumab in the treatment of atypical hemolytic uremic syndrome (aHUS). They report sustained improvements in hematologic parameters, continued safety, and additional improvements in kidney function with extended treatment.
openaire   +2 more sources